These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

916 related articles for article (PubMed ID: 17414590)

  • 1. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.
    Bermúdez-Pirela VJ; Cano C; Medina MT; Souki A; Lemus MA; Leal EM; Seyfi HA; Cano R; Ciscek A; Bermúdez-Arias F; Contreras F; Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):194-202. PubMed ID: 17414590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
    Derosa G; Carbone A; Franzetti I; Querci F; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Res Clin Pract; 2012 Oct; 98(1):51-60. PubMed ID: 22682949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
    Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
    J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes.
    Mu PW; Chen YM; Lu HY; Wen XQ; Zhang YH; Xie RY; Shu J; Wang MM; Zeng LY
    Diabetes Metab Res Rev; 2012 Mar; 28(3):236-40. PubMed ID: 21898754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study to evaluate the effect of l-carnitine plus glimepiride versus glimepiride alone on insulin resistance in type 2 diabetic patients.
    El-Sheikh HM; El-Haggar SM; Elbedewy TA
    Diabetes Metab Syndr; 2019; 13(1):167-173. PubMed ID: 30641691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.
    Moon JS; Ha KS; Yoon JS; Lee HW; Lee HC; Won KC;
    Acta Diabetol; 2014 Apr; 51(2):277-85. PubMed ID: 24445656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy.
    Yu HM; Kim SJ; Chun SW; Park KY; Lim DM; Lee JM; Hong JH; Park KS
    Diabetes Res Clin Pract; 2019 Sep; 155():107796. PubMed ID: 31326458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
    Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin.
    Derosa G; Franzetti I; Gadaleta G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Jun; 17(3):143-50. PubMed ID: 15334791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
    Chon S; Rhee SY; Ahn KJ; Baik SH; Park Y; Nam MS; Lee KW; Yoo SJ; Koh G; Lee DH; Kim YS; Woo JT;
    Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.